Posted by Michael Wonder on 26 Sep 2020
Medicines for haemophilia remain in the high-cost protection after TLV's reconsideration
25 September 2020 - The costs of factor IX concentrate, which is used in the treatment of haemophilia B, are reduced after the TLV has reconsidered the subsidy and regions and companies have signed side agreements.
All factor IX concentrates remain in the high-cost protection.
